Rongrong Zhou

Publication Activity (10 Years)

Years Active: 2021-2024
Publications (10 Years): 17

Top Topics

Systematic Review

Cerebrospinal Fluid

Epidermal Growth Factor Receptor

Top Venues

Journal of cancer research and clinical oncology

Journal for immunotherapy of cancer

Therapeutic advances in medical oncology

Cancer medicine

This page only lists publications with an associated author ORCID identifier.

Publications

Lishui Niu, Honghua Wu, Ruihuan Gao, Liu Chen, Jiangtao Wang, Hexin Duan, Yujiao Long, Yi Xie, Qin Zhou, Rongrong Zhou
Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT. Journal of cancer research and clinical oncology 150 (2) (2024)
Lishui Niu, Honghua Wu, Ruihuan Gao, Liu Chen, Jiangtao Wang, Hexin Duan, Yujiao Long, Yi Xie, Qin Zhou, Rongrong Zhou
Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT. Journal of cancer research and clinical oncology 150 (2) (2024)
Wentao Tian, Lishui Niu, Rongrong Zhou, Ziqi Wang, Jiaoyang Ning, Ruoyu Lu, Yin Shi, Zhaohua Tan
Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer. Cancer medicine 13 (16) (2024)
Wentao Tian, Lishui Niu, Yin Shi, Shuishi Li, Rongrong Zhou
First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis. Therapeutic advances in medical oncology 16 (2024)
Wentao Tian, Lishui Niu, Yin Shi, Shuishi Li, Rongrong Zhou
First-line treatments for advanced non-squamous non-small cell lung cancer with immune checkpoint inhibitors plus chemotherapy: a systematic review, network meta-analysis, and cost-effectiveness analysis. Therapeutic advances in medical oncology 16 (2024)
Wentao Tian, Lishui Niu, Rongrong Zhou, Ziqi Wang, Jiaoyang Ning, Ruoyu Lu, Yin Shi, Zhaohua Tan
Cost-effectiveness analysis of osimertinib plus chemotherapy for patients with EGFR-mutated advanced non-small cell lung cancer. Cancer medicine 13 (16) (2024)
Lishui Niu, Honghua Wu, Ruihuan Gao, Liu Chen, Jiangtao Wang, Hexin Duan, Yujiao Long, Yi Xie, Qin Zhou, Rongrong Zhou
Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT. Journal of cancer research and clinical oncology 150 (2) (2024)
Lishui Niu, Honghua Wu, Ruihuan Gao, Liu Chen, Jiangtao Wang, Hexin Duan, Yujiao Long, Yi Xie, Qin Zhou, Rongrong Zhou
Optimal sequence of LT for symptomatic BM in EGFR-mutant NSCLC: a comparative study of first-line EGFR-TKIs with/without upfront LT. Journal of cancer research and clinical oncology 150 (2) (2024)
Fuxing Deng, Zhiyuan Liu, Wei Fang, Lishui Niu, Xianjing Chu, Quan Cheng, Zijian Zhang, Rongrong Zhou, Guang Yang
MRI radiomics for brain metastasis sub-pathology classification from non-small cell lung cancer: a machine learning, multicenter study. Physical and engineering sciences in medicine (2023)
Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou
Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. Journal for immunotherapy of cancer 11 (3) (2023)
Wentao Tian, Xianjing Chu, Guilong Tanzhu, Rongrong Zhou
Optimal timing and sequence of combining stereotactic radiosurgery with immune checkpoint inhibitors in treating brain metastases: clinical evidence and mechanistic basis. Journal of translational medicine 21 (1) (2023)
Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou
Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. Journal for immunotherapy of cancer 11 (3) (2023)
Gang Xiao, Lifeng Li, Guilong Tanzhu, Zhiyuan Liu, Xuan Gao, Xin Wan, Desheng Xiao, Liu Chen, Xuefeng Xia, Rongrong Zhou
Heterogeneity of tumor immune microenvironment of EGFR/ALK-positive tumors versus EGFR/ALK-negative tumors in resected brain metastases from lung adenocarcinoma. Journal for immunotherapy of cancer 11 (3) (2023)
Guilong Tanzhu, Liu Chen, Gang Xiao, Wen Shi, Haiqin Peng, Dikang Chen, Rongrong Zhou
The schemes, mechanisms and molecular pathway changes of Tumor Treating Fields (TTFields) alone or in combination with radiotherapy and chemotherapy. Cell death discovery 8 (1) (2022)
Zhiyong Deng, Liang Cui, Pansong Li, Nianjun Ren, Zhe Zhong, Zhi Tang, Lei Wang, Jianwu Gong, Haofeng Cheng, Yanfang Guan, Xin Yi, Xuefeng Xia, Rongrong Zhou, Zhengwen He
Genomic comparison between cerebrospinal fluid and primary tumor revealed the genetic events associated with brain metastasis in lung adenocarcinoma. Cell death & disease 12 (10) (2021)
Gang Xiao, Xuan Gao, Lifeng Li, Chao Liu, Zhiyuan Liu, Haiqin Peng, Xuefeng Xia, Xin Yi, Rongrong Zhou
An Immune-Related Prognostic Signature for Predicting Clinical Outcomes and Immune Landscape in IDH-Mutant Lower-Grade Gliomas. Journal of oncology 2021 (2021)
Zhengbo Song, Ling Yang, Zhipeng Zhou, Pansong Li, Wenxian Wang, Guoping Cheng, Rongrong Chen, Lianpeng Chang, Yiping Zhang, Yanfang Guan, Xuefeng Xia, Xin Yi, Rongrong Zhou, Ming Chen
Genomic profiles and tumor immune microenvironment of primary lung carcinoma and brain oligo-metastasis. Cell death & disease 12 (1) (2021)